Current best practices and rationalistic perspectives in causation-based prevention, early detection and multidisciplinary treatment of breast and gastric cancer

Gastric & Breast Cancer e-journal
DOI: 10.2122/gbc.2008.0075


Minimal residual disease in breast cancer: Can it be used as prognostic marker?
George Zografos M.D, PhD.

Affiliation: Head of the Breast Unit, Head of 1st Department of Propaedeutic Surgery, University of Athens, Greece.

Tel: +306932524836


Since there is no abstract, we provide the first paragraph

Beyond “classic” prognostic factors and HER2/ER status [1] there is an urgent need for molecular class II prognostic and class III predictive biomarkers not only for breast cancer but also for most solid cancers [2-5]. Currently, this goal appears to be achievable for hereditary breast cancer [6-8]. However, despite efforts and use of high-throughput technologies, no robust prognostic biomarker has been validated for wide clinical use in sporadic breast cancer. Could micrometastatic disease in lymph nodes be used as prognostic marker?

Online ISSN : 1109 - 7647
   Print ISSN : 1109 - 7655

We subscribe to the HONcode principles of the HON Foundation. Click to verify. We subscribe to the HONcode principles. Verify here.
please, read our policy about privacy and confidentiality of information and transparency of sponsorship

last update: 3 February 2004